Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CARGO Therapeutics
Firicabtagene autoleucel (firi-cel) is an autologous CAR T-cell therapy targeting CD22, a common B-cell antigen widely expressed in LBCL. This Phase 2 study is designed to evaluate the safety and the efficacy of firi-cel in patients with R/R LBCL that has progressed after CD19-directed CAR T-cell therapy. The study is designed to treat up to 123 patients with a single infusion of firi-cel.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged ≥18 years
Relapsed or refractory, histologically confirmed large B-cell lymphoma.
Must have relapsed or refractory diseae after last therapy.
For enrollment in cohort 1, patients must have previously received a CD19-directed CAR T-cell therapy
For enrollment in cohort 3, patients must have received at least two prior lines of therapy including a bispecific T-cel engaging antibody therapy.
Must have at least one radiographically measurable lesion.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematological, renal, and liver function
Willing and able to remain within 1 hour of the treating center for at least 4 weeks after infusion.
You may not be if
Clinically significant concurrent medical illness
Active fungal, bacterial, viral or other infection.
Prior allogeneic stem cell transplant or allogeneic cell therapy
Clareo Health | A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
